Skip to search formSkip to main contentSkip to account menu

17-aminogeldanamycin

National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

BenzoquinonesLactams, Macrocyclic

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
17-Aminogeldanamycin Inhibits Constitutive Nuclear Factor-Kappa B (NF-κB) Activity in Patient-Derived Melanoma Cell Lines
Melanoma remains incurable skin cancer, and targeting heat shock protein 90 (HSP90) is a promising therapeutic approach. In this… 
2019
2019
17-Aminogeldanamycin selectively diminishes IRE1α-XBP1s pathway activity and cooperatively induces apoptosis with MEK1/2 and BRAFV600E inhibitors in melanoma cells of different genetic subtypes
Outcomes of melanoma patient treatment remain unsatisfactory despite accessibility of oncoprotein-targeting drugs and… 
2011
2011
Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemia
Background In preclinical studies the heat shock protein 90 (Hsp90) inhibitor tanespimycin induced down-regulation of checkpoint… 
Highly Cited
2005
Highly Cited
2005
Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine.
Previous studies demonstrated that ataxia telangiectasia mutated- and Rad3-related (ATR) kinase and its downstream target… 
Highly Cited
2004
Highly Cited
2004
Synthesis and biological activities of novel 17-aminogeldanamycin derivatives.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)